BioXcel Therapeutics Inc at Bank of America Healthcare Conference Transcript
Welcome to the final day of the Bank of America Healthcare Conference. My name is Greg Harrison. I'm one of the biotech analysts here at BofA. It's my pleasure today to introduce Vimal Mehta, Chief Executive Officer of BioXcel Therapeutics; Matt Wiley, Chief Commercial Officer; and Vince O'Neill, Chief Medical Officer. Vimal, would you like to start off with some opening comments and then we can get into the Q&A?
Sure. Good morning, everyone, and thank you, Greg, for hosting us here today. BioXcel Therapeutics is a biopharma company using AI platform to develop transformative medicines in neuroscience as well as in immuno-oncology. It has been a very transformative year already, 2022, with the approval of our first drug product. We have 2 lead candidate, BXCL501, which is for acute treatment of agitation resulting from various neuropsychiatric conditions, as well as BXCL701, which is an activator of innate
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |